» Articles » PMID: 1674549

Blocking of Human Immunodeficiency Virus Infection Depends on Cell Density and Viral Stock Age

Overview
Journal J Virol
Date 1991 Jun 1
PMID 1674549
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Quantitative infectivity assays were used to study how the blocking activity of soluble CD4 (sCD4) is affected by sCD4 concentration, target cell density, and viral stock age. During incubation with 20 nM sCD4, human immunodeficiency virus type 1 (HIV-1) stocks underwent irreversible inactivation. In contrast, inactivation with 2 nM sCD4 was almost entirely reversible. At lower sCD4 concentrations (less than or equal to 2 nM) and target cell densities of 6.25 x 10(4) ml-1, sCD4 blocking activity for HIV-1 gave a gp120-sCD4 association constant (Kassoc) of 1.7 x 10(9) M-1, which agrees with chemical measurements. At the higher density of 1.6 x 10(7) cells ml-1, however, the blocking activity was 20-fold less. During incubation of HIV-1 stock optimized for infectivity by rapid harvest, sCD4 blocking activity increased 20-fold during a 3-h window. These results show that competitive blocking activity depends strongly on target cell density and virion age. Thus, unappreciated variations in HIV stocks and assay conditions may hinder comparisons of blockers from laboratory to laboratory, and the age of HIV challenge stocks may influence studies of drug and vaccine efficacy. The results also suggest that blocking of viral particles in lymphoid compartments will require very high competitive blocker concentrations, which may explain the refractory outcomes from sCD4-based drug trials in humans.

Citing Articles

Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design.

Sealy R, Dayton B, Finkelstein D, Hurwitz J Viruses. 2021; 13(5).

PMID: 34064894 PMC: 8151930. DOI: 10.3390/v13050884.


Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Klasse P Adv Biol. 2016; 2014.

PMID: 27099867 PMC: 4835181. DOI: 10.1155/2014/157895.


Molecular determinants of the ratio of inert to infectious virus particles.

Klasse P Prog Mol Biol Transl Sci. 2015; 129:285-326.

PMID: 25595808 PMC: 4724431. DOI: 10.1016/bs.pmbts.2014.10.012.


Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).

Agrawal N, Leaman D, Rowcliffe E, Kinkead H, Nohria R, Akagi J PLoS One. 2011; 6(6):e21339.

PMID: 21738637 PMC: 3124497. DOI: 10.1371/journal.pone.0021339.


Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Klasse P Virology. 2007; 369(2):245-62.

PMID: 17825343 PMC: 2317823. DOI: 10.1016/j.virol.2007.06.044.


References
1.
Javaherian K, Langlois A, LaRosa G, Profy A, Bolognesi D, Herlihy W . Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990; 250(4987):1590-3. DOI: 10.1126/science.1703322. View

2.
Gelderblom H, Reupke H, Pauli G . Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?. Lancet. 1985; 2(8462):1016-7. DOI: 10.1016/s0140-6736(85)90570-7. View

3.
Wang J, Yan Y, Garrett T, Liu J, Rodgers D, Garlick R . Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 1990; 348(6300):411-8. DOI: 10.1038/348411a0. View

4.
McKeating J, McKnight A, Moore J . Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol. 1991; 65(2):852-60. PMC: 239825. DOI: 10.1128/JVI.65.2.852-860.1991. View

5.
Moore J, McKeating J, Norton W, Sattentau Q . Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol. 1991; 65(3):1133-40. PMC: 239879. DOI: 10.1128/JVI.65.3.1133-1140.1991. View